Gene Expression Profiling Provides an Improved Characterization of CD79B-Mutated Diffuse Large B-Cell Lymphomas

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse Large B-cell Lymphomas (DLBCLs) are heterogeneous cancers.
• CD79B and MYD88 mutations characterize a unique DLBCL subtype associated with poor prognosis.
• Gene expression profiles in mutated DLBCLs remain incompletely understood.

Purpose of the Study:

• To compare gene expression patterns in DLBCLs based on CD79B mutational status.
• To identify novel molecular targets for therapeutic intervention in DLBCL.

Main Methods:

• RNA expression profiling of 770 genes in 48 treatment-naïve DLBCLs.
• Immunohistochemical analysis of upregulated genes.
• Survival analysis stratified by mutation status and gene expression.

Main Results:

• CD79B-mutated DLBCLs showed upregulation of CARD11, NF-κB targets (NFKBIZ, IL10, IL12A, PIM1, BCL2A1), ARNT2, WNT11, apoptosis-related genes (BID, granzyme B), and cell cycle regulators (RUNX1, RUNX1T1, RASGRF1).
• TP53 mutations correlated with poorer survival.
• No significant survival differences were observed based on CD79B/MYD88 mutation status or specific gene expression profiles in this cohort.

Conclusions:

• Novel genes, beyond NF-κB signaling, are upregulated in CD79B-mutated DLBCLs.
• These findings offer potential new therapeutic targets for this aggressive DLBCL subgroup.
• Further characterization of CD79B-mutated DLBCLs is crucial for improved treatment strategies.